Table 4.
Association between Patient Characteristics and Membership into Latent Classes of Adherence to DOACs
| Initiators in months 6–11 (Class 1) n=800 | Initiators in months 1–5 (Class 2) n=1,368 | Patients with suboptimal and decreasing adherence (Class 3) n=2,267 | Continuously adherent users (Class 4) n=5,043 | P valuea | |
|---|---|---|---|---|---|
| Age | 1.00 (0.99, 1.01) | 1.01 (1.00, 1.02) | 1.00 (0.99, 1.00) | 1 | 0.20 |
| Male | 0.97 (0.82, 1.14) | 0.90 (0.79, 1.03) | 1.14 (1.02, 1.27) | 1 | 0.02 |
| Race | 0.003a | ||||
| White | ref | ref | ref | ref | |
| Black | 1.17 (0.83, 1.66) | 1.98 (0.73, 1.32) | 1.54 (1.23, 1.92) | 1 | |
| Other | 1.25 (0.90, 1.73) | 1.07 (0.80, 1.42) | 0.93 (0.73, 1.19) | 1 | |
| Medicaid | 1.59 (1.14, 2.22) | 1.09 (0.85, 1.40) | 1.01 (0.82, 1.24) | 1 | 0.05 |
| Income Subsidy | 0.73 (0.54, 0.99) | 1.00 (0.81, 1.24) | 1.02 (0.85, 1.21) | 1 | 0.21 |
| SES | 0.95 (0.88, 1.03) | 1.01 (0.94, 1.07) | 0.92 (0.87, 0.97) | 1 | 0.01 |
| Dissimilarity | 0.77 (0.47, 1.26) | 1.20 (0.81, 1.79) | 0.81 (0.58, 1.12) | 1 | 0.24 |
| Rural | 1.07 (0.88, 1.30) | 1.07 (0.91, 1.25) | 0.96 (0.84, 1.10) | 1 | 0.61 |
| Region | <0.001a | ||||
| Midwest | 1.01 (0.80, 1.27) | 1.08 (0.89, 1.30) | 1.31 (1.13, 1.52) | 1 | |
| Northeast | ref | ref | ref | ||
| Southeast | 1.07 (0.85, 1.33) | 1.43 (1.19, 1.70) | 1.17 (1.01, 1.36) | 1 | |
| Southwest | 1.41 (1.06, 1.87) | 1.35 (1.06, 1.72) | 1.27 (1.04, 1.55) | 1 | |
| West | 1.12 (0.85, 1.47) | 1.18 (0.94, 1.48) | 1.30 (1.08, 1.56) | 1 | |
| CHA2DS2-VAScc | 1.00 (0.93, 1.06) | 0.98 (0.93, 1.03) | 0.97 (0.92, 1.01) | 1 | 0.46 |
| HAS-BLEDc | 1.11 (1.00, 1.24) | 1.13 (1.04, 1.24) | 1.15 (1.07, 1.23) | 1 | <0.001a |
| AD or Dementiac | 1.26 (1.00, 1.58) | 1.30 (1.09, 1.56) | 1.09 (0.93, 1.28) | 1 | 0.02 |
| NSAID or Antiplatelet Usec | 0.94 (0.77, 1.16) | 0.96 (0.82, 1.14) | 0.92 (0.81, 1.06) | 1 | 0.69 |
| Antiarrhythmic Medication Useb, c | 0.84 (0.63, 1.13) | 0.72 (0.56, 0.92) | 1.33 (1.12, 1.57) | 1 | <0.001a |
Abbreviations: SES: social economic status; AD: Alzheimer’s disease; NSAID, nonsteroidal anti-inflammatory drugs;
a.
Results were statistically significant after the Holm modified Bonferroni correction;
b.
Antiarrhythmic medications included amiodarone, dronaderone, and verapamil;
c.
Clinical characteristics were defined based on 12 months of claims data prior to AF diagnosis.